Form 4: BioCryst Pharmaceuticals Director Receives Equity Compensation Package

Machelle Sanders, a Director at BioCryst Pharmaceuticals, Inc., has received an automatic grant of Restricted Stock Units and stock options as part of her non-employee director compensation.

Summary

• Machelle Sanders, a Director of BioCryst Pharmaceuticals, Inc. (BCRX), received an automatic grant of 12,500 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 12, 2025.
• These RSUs were granted at a price of $0 and are set to vest on the first anniversary of the grant date, June 12, 2026.
• Additionally, Ms. Sanders received an automatic grant of 27,181 stock options on June 12, 2025, with an exercise price of $10.4 per share.
• These stock options become exercisable on June 12, 2026, and have an expiration date of June 12, 2035.
• Following these transactions, Ms. Sanders beneficially owns 40,242 shares of Common Stock and 27,181 derivative securities (stock options) directly.
• The grants were made pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.
• A Power of Attorney dated June 11, 2025, authorizes Alane P. Barnes and Sara A. Mykrantz to prepare and file SEC reports, including Forms 3, 4, and 5, on behalf of Machelle Sanders.

Sentiment

Score: 6

Explanation: The document reports a routine and expected equity compensation grant to a director, which is generally positive as it aligns interests, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The equity grants align the director's financial interests with those of the shareholders, promoting long-term value creation.
• The compensation package is part of a pre-established Non-Employee Director Compensation Policy, indicating a structured and transparent approach to governance.

Future Outlook

The Restricted Stock Units are scheduled to vest on June 12, 2026, and the stock options will become exercisable on the same date, expiring on June 12, 2035. These future dates represent key milestones for the director's equity compensation.

Management Comments

• The grants were made pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.

Industry Context

This filing reflects a routine compensation event for a non-employee director in the biotechnology and pharmaceutical industry. It is common practice for companies in this sector to use equity-based compensation to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The use of a combination of Restricted Stock Units (RSUs) and stock options for non-employee director compensation is a standard practice across the biotechnology and broader corporate landscape, aiming to align director incentives with company performance and shareholder returns.
• The automatic nature of the grant, pursuant to a defined compensation policy, is also a common governance practice to ensure transparency and reduce potential for discretionary influence.

Corporate Governance

Related Party Transactions

• The grants of Restricted Stock Units and stock options to Machelle Sanders, a director, constitute related party transactions as they involve compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholder value, potentially leading to more focused decision-making aimed at long-term company performance.
• Employees: No direct impact mentioned, but a well-governed company with aligned leadership can indirectly benefit all employees.
• Director (Machelle Sanders): Receives equity compensation, which is a significant component of her remuneration and incentivizes her to contribute to the company's success.

Next Steps

• Vesting of 12,500 Restricted Stock Units on June 12, 2026.
• Stock options for 27,181 shares becoming exercisable on June 12, 2026.
• Potential exercise of stock options by Machelle Sanders between June 12, 2026, and June 12, 2035.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, Corporate Governance